as of 12-12-2025 3:39pm EST
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.2B | IPO Year: | 2024 |
| Target Price: | $47.80 | AVG Volume (30 days): | 361.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.43 - $42.27 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Operating Officer
Avg Cost/Share
$30.10
Shares
5,000
Total Value
$150,486.50
Owned After
171,928
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$25.12
Shares
8,500
Total Value
$214,090.64
Owned After
406,486
Chief Executive Officer
Avg Cost/Share
$25.18
Shares
10,916
Total Value
$275,046.92
Owned After
35,978
Chief Scientific Officer
Avg Cost/Share
$25.95
Shares
8,500
Total Value
$219,196.21
Owned After
406,486
Chief Executive Officer
Avg Cost/Share
$25.95
Shares
10,916
Total Value
$281,729.14
Owned After
35,978
Chief Executive Officer
Avg Cost/Share
$26.63
Shares
76,420
Total Value
$2,011,197.18
Owned After
35,978
Chief Scientific Officer
Avg Cost/Share
$24.27
Shares
8,500
Total Value
$205,648.68
Owned After
406,486
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gault Cheryl | RAPP | Chief Operating Officer | Nov 26, 2025 | Sell | $30.10 | 5,000 | $150,486.50 | 171,928 | |
| Bredt David | RAPP | Chief Scientific Officer | Nov 17, 2025 | Sell | $25.12 | 8,500 | $214,090.64 | 406,486 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Nov 17, 2025 | Sell | $25.18 | 10,916 | $275,046.92 | 35,978 | |
| Bredt David | RAPP | Chief Scientific Officer | Oct 15, 2025 | Sell | $25.95 | 8,500 | $219,196.21 | 406,486 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Oct 15, 2025 | Sell | $25.95 | 10,916 | $281,729.14 | 35,978 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Sep 17, 2025 | Sell | $26.63 | 76,420 | $2,011,197.18 | 35,978 | |
| Bredt David | RAPP | Chief Scientific Officer | Sep 15, 2025 | Sell | $24.27 | 8,500 | $205,648.68 | 406,486 |
See how RAPP stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "RAPP Rapport Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.